Background: Many people find it difficult to lose weight, but it is even more of a challenge to maintain the achieved weight loss. It is typical for patients on weight-loss medication to regain most of their weight when discontinuing their treatment. Our hypothesis was that the novel weight loss product EMP16, a modified release combination product using orlistat and acarbose, would be associated with less weight regain after a 6-month intervention period. Methods: After completing a 6-month study testing two doses of EMP16 versus placebo, 125 participants agreed to return for a followup visit six months after discontinuing the study treatment. In the intervention period, EMP16 120 mg orlistat/ 40 mg acarbose, EMP16 150/50 and placebo had been compared. At the follow-up visit weight, HbA1c and blood pressure (BP) were measured. The participants remained blinded to their treatment, but some of the clinical personnel had access to un-blinded data. Results: Of the 125 participants, 97 (mean (SD) age 52.6 (11.6) years, 71% females) attended the 6-month follow-up visit. The mean (confidence interval) relative weight loss at the end of the treatment period was -6.6 (-8.1 to -5.0) -7.0 (-8.4 to -5.5) and -1.3 (-2.7 to 0.1) % in the EMP16 120/40, EMP16 150/50 and placebo groups, respectively. At follow-up six months after discontinuing treatment, the mean (CI) relative weight loss was -1.6 (-3.7 to 0.5), -2.8 ( -4.4 to -1.2), and -0.3 (-2.6 to 1.9) %. There were no differences in HbA1c between the groups at the follow-up period. Systolic BP returned to baseline in the intervention groups, but not in the placebo group 1.1 (-1.7 to 3.9), 2.7 (-0.5 to 5.9), and -4.5 (-7.9 to -1.0) mmHg; EMP16 120/40, EMP16 150/50 and placebo group, respectively. The same pattern was observed in diastolic BP. Conclusions: Six months after treatment with a modified release combination product using orlistat and acarbose the maintained weight loss was greater than observed in similar studies with other weightloss medications. This finding strengthens our hypothesis that EMP16 is associated with less of a weight rebound than other weight-loss medication. The results of this explorative study have to be investigated further in a larger population and possibly after medication for a longer time.